SFBC International has changed its name to PharmaNet Development Group, Inc. after receiving approval from its shareholders at the annual meeting. The company has also named John P. Hamill to the role of executive vice president and chief financial officer, David Natan to executive vice president, Reporting and Analysis, and chief accounting officer, and Thomas J. Newman, M.D. to executive vice president, Late Stage Development. Dr. Newman will retain his responsibilities as chief operating officer of the company’s late-stage business. In addition, Anne-Marie Hess was appointed executive director, investor relations and corporate communications.

“The PharmaNet Development Group name builds on the reputation and prominent market positions of PharmaNet, Anapharm and our other subsidiaries as a leading drug development organization committed to patient safety and providing excellent service and integrated global drug development capabilities to our clients,” said Jeffrey P. McMullen, president and chief executive officer of PharmaNet Development Group. “We have realigned corporate functions and established the right corporate executive management team to focus on building a long-term, sustainable business that will enhance client and shareholder value.”

The company’s early-stage clinical development business will continue to operate under its existing brands, including Anapharm, and the late-stage clinical development business will continue to operate under its existing brand, PharmaNet.